Welcome to Exalon

Your partner for high quality eCTDs, regulatory submission services and EVMPD support

Our highly experienced team of regulatory affairs, documentation and IT professionals provides a comprehensive set of services covering all aspects of the electronic drug regulatory affairs business.

We are publishing eCTD submissions for of all types of applications (e.g. medicinal product dossiers, master files) in all regions. Our services include submission hosting, processing of individual submission documents as well as consultancy in all questions of electronic drug regulatory business.

In addition to our electronic publishing services we support the registration of your medicinal products in xEVMPD in acc. to Article 57(2) second subparagraph of Regulation 726/2004.

We provide consulting and training regarding eCTD and xEVMPD requirements and support the implementation of electronic submission and tracking systems in the pharmaceutical industry.

 

eCTD implementation – interactive map

 

AE – United Arab Emirates – GCC
AM – Armenia – EAEU “eCTD”
AT – Austria
AU – Australia
BE – Belgium
BG – Bulgaria
BH – Bahrain – GCC
BR – Brazil – planned
BY – Belarus – EAEU “eCTD”
CA – Canada
CH – Switzerland
CN – China
CY – Cyprus
CZ – Czechia
DE – Germany
DK – Denmark
EE – Estonia
EG – Egypt – planned
ES – Spain
FI – Finland
FR – France
GB – United Kingdom
GR – Greece
HR – Croatia
HU – Hungary
IE – Ireland
IS – Iceland
IT – Italy
JO – Jordan
JP – Japan
KE – Kenya – planned
KG – Kyrgyzstan – EAEU “eCTD”
KR – South Korea
KW – Kuwait – GCC
KZ – Kazakhstan – EAEU “eCTD”
LI – Liechtenstein
LT – Lithuania
LU – Luxembourg
LV – Latvia
MT – Malta
NL – Netherlands
NO – Norway
OM – Oman – GCC
PL – Poland
PT – Portugal
QA – Qatar – GCC
RO – Romania
RS – Serbia – planned
RU – Russia – EAEU “eCTD” (technically different to ICH eCTD)
SA – Saudi Arabia – GCC
SE – Serbia
SG – Singapore – planned
SI – Slovenia
SK – Slovakia
TH – Thailand
TW – Taiwan
US – United States
ZA – South Africa

 

Our X Feed

Pharmaceutical industry stakeholders are seeking clearer implementation guidance for the transition to ICH M4Q(R2), particularly on timelines, legacy product handling, and minimizing rework for existing dossiers. Read the RAPS article: #ICH #eCTD

FDA & EMA urge pharma to pilot eCTD 4.0 now! EU mandate hits 2027 for centralized products; FDA eyes 2029. Early testing = smoother submissions. Who's joining the pilot? #eCTD #RegulatoryAffairs #PharmaTech

FDA, EMA officials encourage companies to pilot eCTD 4.0

The end of the year is a perfect moment to say thank you.

We are grateful to our customers, partners, and team for a year of cooperation and shared success.

Season’s Greetings and best wishes for the New Year from Exalon!

Load More...